Statistics from Altmetric.com
- ACR, American College of Rheumatology
- PASI, psoriasis area and severity index
- PsA, psoriatic arthritis
- PsARC, psoriatic arthritis response criteria
Infliximab was shown to be effective and safe in controlled trials of psoriatic arthritis (PsA).1–,4 In an open-label study, we reported a notable clinical benefit accompanied by clearing and healing of psoriatic skin lesions.5 Thus, we conducted this study to evaluate the efficacy and safety of infliximab in patients with active PsA and recalcitrant psoriasis in whom treatment with disease-modifying antirheumatic drugs had failed. Thirty two patients who had a negative purified protein derivative skin test and normal chest radiographs were included. All had an active disease, defined as ⩾6 tender or swollen joints count, psoriasis area and severity index (PASI) score ⩾10,6 and erythrocyte sedimentation rate ⩾28 mm Hg/h or C reactive protein concentration …
Competing interests: None declared.
Published Online First 23 October 2006
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.